King divests Prefest
Barr acquires King's hormone replacement therapy Prefest for approximately $15 mil. The deal is part of King's strategy to divest "many, if not all" of its women's health products, King said Nov. 22. Barr and King are involved in pending litigation over patents related to Prefest (estradiol/norgestimate); the case will be voluntarily dismissed after the product acquisition. King has plans to merge with Mylan (1"The Pink Sheet" Nov. 1, 2004, p. 21)...
You may also be interested in...
Cognoa said it will submit its AI-powered digital app for early detection of autism for de novo clearance with the US FDA. See what the company’s senior medical director of clinical adoption said about it here.
Congress should give FDA more flexibility to administer orphan designations, such as the ability to revoke designations later if the disease prevalence grows beyond the rare disease threshold.
In sign of how much has changed in four years, industry might be better off if Biden takes CAP’s advice and launches ‘march-in’ actions to address pricing of COVID products.